Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.
Metrics to compare | ELVN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipELVNPeersSector | |
---|---|---|---|---|
P/E Ratio | −14.4x | −0.6x | −0.5x | |
PEG Ratio | 24.38 | −0.01 | 0.00 | |
Price/Book | 4.7x | 0.3x | 2.6x | |
Price / LTM Sales | - | 1.8x | 3.1x | |
Upside (Analyst Target) | 72.5% | 120.4% | 51.1% | |
Fair Value Upside | Unlock | 16.2% | 8.9% | Unlock |